|1.||Druilhe, Pierre: 4 articles (01/2011 - 09/2004)|
|2.||Theisen, Michael: 3 articles (04/2015 - 09/2004)|
|3.||Kim, Hee Jin: 3 articles (02/2015 - 05/2013)|
|4.||Na, Duk L: 3 articles (02/2015 - 05/2013)|
|5.||Kim, Sung Tae: 3 articles (02/2015 - 05/2013)|
|6.||Seo, Sang Won: 3 articles (02/2015 - 05/2013)|
|7.||Werring, David J: 3 articles (02/2015 - 05/2013)|
|8.||Park, Jae-Hyun: 2 articles (02/2015 - 05/2013)|
|9.||Kim, Jung-Hyun: 2 articles (02/2015 - 11/2013)|
|10.||Weiner, Michael W: 2 articles (11/2013 - 05/2013)|
03/01/2000 - "The combination of these two mechanisms of action makes SGB-017 an effective AED in several different animal models of epilepsy."
03/01/2000 - "However, SGB-017 is effective in several animal models of epilepsy that are unresponsive to NMDA antagonists. "
07/01/1998 - "ADCI is a mild NMDA antagonist and a use-dependent blocker of voltage-gated sodium channels, the combined effect of which, in preclinical studies, has been improved efficacy in the treatment of epileptic seizures. "
07/01/1998 - "ADCI is an NMDA antagonist and a sodium channel antagonist which is under development by Neurogen and Wyeth-Ayerst as a potential treatment for epilepsy, seizures and stroke. "
06/01/1995 - "In the present study, we sought to determine if tolerance develops to the anticonvulsant activity of ADCI, using the maximal electroshock (MES) test to assess seizure protection. "
10/01/1991 - "In common with other NMDA antagonists, ADCI retarded the development of amygdaloid kindled seizures in rats, but failed to attenuate the afterdischarge duration in fully kindled animals. "
10/01/1991 - "ADCI was also protective against chemically induced seizures in mice, including those produced by 4-aminopyridine (ED50, 7.1 mg/kg s.c.) and pentylenetetrazol (ED50, 37.4 mg/kg s.c.). "
03/13/1992 - "In contrast to the lack of activity of other NMDA antagonists, phencyclidine and ADCI [(+/-)-aminocarbonyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine] were potent antagonists of DTX-induced seizures."
03/01/1992 - "ADCI and dizocilpine suppressed the severity and occurrence of the withdrawal seizures in a dose-dependent fashion, whereas carbamazepine was ineffective in blocking the withdrawal seizures. "
04/01/2015 - "Findings here suggest a potential usefulness of the ADCI assay as a correlate of protection to guide malaria vaccine studies. "
04/01/2015 - "High ADCI activity was significantly associated with reduced risk against malaria. "
01/01/2013 - "Protective immunity against malaria requires the induction of humoral, antibody-dependent cellular inhibition (ADCI) and effector and memory cell responses. "
10/01/2009 - "Data showed that, during a malaria attack, some patients' MO can exert a strong ADCI activity. "
09/01/1994 - "Accordingly, an assay of antibody-dependent cellular inhibition (ADCI) of parasite growth was used as a means of selecting for molecules capable of inducing protective immunity to malaria. "
10/01/2009 - "In the group of patients with the highest percentages and absolute numbers of CD14(hi)CCR2+CX3CR1+ MO and the highest mean levels of ADCI activity, blood parasitemias were lower (0.14+/-0.34%) than in the second group (1.30+/-3.34%; p = 0.0053). "
08/01/2011 - "Interestingly, in the ADCI test, higher levels of tumour necrosis factor alpha (TNF-α) were observed in the supernatant from cultures with higher parasitemias. "
05/01/2001 - "The results suggest that, among the different isotypes present in the serum of semi-immune individuals, parasite antigen-specific IgG3 in particular may play an important role in controlling parasitemia via an ADCI mechanism involving monocyte- derived mediators."
08/01/1995 - "Results obtained so far suggest that (a) merozoite uptake by monocytes (MN) as well as by polymorphonuclear cells has little influence on the course of parasitemia; (b) the ADCI effect is mediated by a soluble factor released by MN; (c) this or these factors are able to block the division of surrounding intraerythrocytic parasites at the one nucleus stage; (d) the critical triggering antigen(s) targeted by effective Abs would appear to be associated with the surface of merozoites, as opposed to that of infected red blood cells; (e) the MN receptor for Abs effective in ADCI is apparently Fc gamma RII, and not RI; (f) MN function is up- and down-regulated by interferon-gamma and interleukin 4, respectively; and (g) of several potential mediators released by MN, only tumor necrosis factor (TNF) proved of relevance. "
|5.||Alzheimer Disease (Alzheimer's Disease)
02/24/2015 - "Gradient-recalled echo, T2*-weighted MRIs from 232 patients (Alzheimer disease-related cognitive impairment [ADCI], n = 90; subcortical vascular cognitive impairment [SVCI], n = 142) were reviewed for cSS. "
11/01/2013 - "We recruited 230 subjects with normal cognition, 111 subjects with cognitive impairment due to clinically defined Alzheimer's disease (ADCI), and 134 subjects with clinically defined SVCI. "
05/01/2013 - "We included 226 patients: 89 with Alzheimer disease-related cognitive impairment (ADCI) and 137 with subcortical vascular cognitive impairment (SVCI). "
|2.||Sodium Channels (Sodium Channel)
|3.||Immunoglobulin G (IgG)
|5.||IgG Receptors (Fc gamma RI)
|6.||Interleukin-4 (Interleukin 4)
|7.||4-Aminopyridine (4 Aminopyridine)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interferon-gamma (Interferon, gamma)